Credit: Canva
Cancer is a large group of diseases that can start in almost any organ or tissue of the body when abnormal cells grow uncontrollably, and go beyond their usual boundaries to invade adjoining parts of the body. According to the World Health Organization (WHO), it is the second most common cause of death globally, accounting for millions of deaths every year. Lung, prostate, colorectal, stomach and liver cancer are the most common types of cancer in men, while breast, colorectal, lung, cervical and thyroid cancer are the most common among women. However, these are not necessarily the deadliest forms of cancer.
What makes cancer the deadliest depends upon how many people have it and what percentage of those people actually survive. Cancer researchers determine this on the basis of five-year relative survival. This is the percentage of people who are expected to survive the effects of a given cancer, excluding their risk of other possible causes of death, for five years past a diagnosis. It is also important to note that what makes cancer really deadly is that practically no cure for it. A cure for cancer would imply that there are no cancerous cells remaining in the body.
Here are the 5 deadliest cancers in the U.S., according to SEER five-year relative survival data for cases diagnosed between 2014 and 2020.
1. Pancreatic cancer occurs when cells in your pancreas, a gland in your abdomen that aids digestion, mutate and multiply out of control, forming a tumour. Major risk factors include smoking, obesity, diabetes, chronic pancreatitis, certain genetic mutations and environmental chemical exposure.
2. Esophageal cancer develops in the oesophagus, which is the tube that connects your throat to your stomach.
3. Liver cancer and intrahepatic bile duct cancer originate in the liver or bile ducts, often linked to hepatitis infections, heavy alcohol use, obesity, and aflatoxin exposure.
4. Lung and bronchus cancer primarily caused by smoking, secondhand smoke, and environmental pollutants, affects the lungs and airways, making it the leading cause of cancer death in the US.
5. Acute myeloid leukaemia (AML) is an aggressive blood and bone marrow cancer that progresses rapidly, often linked to genetic mutations, radiation exposure, and certain chemicals.
ALSO READ: Why Are Lifestyle Factors Making Millennials Vulnerable To Cancer?
Credit: AI image
The US Food and Drug Administration (FDA) has granted approval to a new drug that could help patients with a rare and life-threatening genetic disorder live longer. The treatment, Lembaz (adrabetadex), is the first drug proven to reduce the risk of death in patients with infantile-onset Niemann-Pick disease type C (NPC).
Announced on November 17, 2026, the approval marks an important development for families affected by the rare disease, which causes progressive neurological damage and can significantly shorten life expectancy.
Lembaz is approved for adults and children weighing at least 7 kg (approximately 15 pounds) whose neurological symptoms began before the age of six. It is administered as an injection directly into the fluid surrounding the spinal cord, a procedure known as an intrathecal injection, every two weeks.
"For the first time, there is a treatment shown to help adults and children with this serious disease live longer," said Acting FDA Commissioner Kyle Diamantas.
The FDA's approval was based on data from 36 patients treated with Lembaz across three clinical studies. Their outcomes were compared to an external control group of patients who had not received the treatment.
The analysis found that patients who received Lembaz had a 55% lower risk of death compared to the control group.
The median overall survival was 8.5 years among patients treated with Lembaz compared to 4.9 years in the control group.
The benefit was observed regardless of whether patients were also receiving miglustat, another medicine used to manage NPC.
Also read: Childhood Obesity: Wegovy Cuts BMI By 10% In Children As Young As 6; What Are The Risks?
Niemann-Pick disease type C is a rare inherited disorder that affects the body's ability to process cholesterol and other fatty substances inside cells.
The condition is caused by changes in either the NPC1 or NPC2 gene. These genes produce proteins that help move cholesterol and other lipids within cells. When these proteins do not function properly, fatty substances accumulate inside cells, affecting organs like liver, spleen and brain. Over time, this causes progressive damage to the nervous system.
Patients may experience difficulties with movement, balance, coordination, speech and swallowing. Some may also face seizures, cognitive difficulties and problems controlling eye movements.
The disease affects approximately one in 150,000 people, according to the FDA. Its symptoms and severity can vary depending on when the disease begins.
Also read: 112 Pregnant Women, 13 Newborns Infected With Measles In US Since 2025: CDC
Infantile-onset NPC refers to cases in which neurological symptoms start before the age of six. These patients experience a more aggressive disease as they face rapid progressive neurological deterioration and a shorter life expectancy.
As the disease advances, children may gradually lose the ability to walk, speak and swallow independently. Difficulties with swallowing can also increase the risk of respiratory complications.
There is currently no cure for NPC, making treatments that can slow disease progression or improve survival important.
Lembaz contains adrabetadex, a cyclodextrin-based medicine made to address the underlying cholesterol processing defect in NPC.
In simple terms, the drug helps move cholesterol trapped inside cells, especially brain cells, so that it can be transported to areas where it is needed.
By targeting this underlying problem, the treatment aims to reduce the cellular damage that comes with the disease.
According to the FDA, hearing impairment, including permanent hearing loss, could be one of the side effects of Lembaz. Hence, patients must undergo hearing assessments before starting the drug and regularly throughout the course.
Other common side effects include balance and coordination problems, fatigue, vomiting, back pain, headache, fever, diarrhoea, nausea and cough.
Credit: AI Image
The US has lost its measles elimination status after 26 years, with Bolivia and Mexico also losing the designation, the Pan American Health Organization (PAHO) announced on Tuesday. The decision follows more than 12 months of continuous measles transmission in the US.
Amid the resurgence, a CDC-led report has identified 112 measles infections among pregnant women in the US between January 2025 and September 2026, along with 13 cases of congenital measles in newborns. Nearly all the women were unvaccinated or had an unknown vaccination status.
The actual number of infections among pregnant women may be higher. A separate CIDRAP News investigation based on state health department data identified at least 167 pregnant women infected in 2025 and 2026.
Also Read: What Happens After Measles Infection? The Hidden Risks That Can Last For Years
The CDC-led report, published in NEJM Evidence journal, found that 108 (96%) of the 112 cases occurred during outbreaks involving 50 or more cases.
Of the infected women, 110 (98%) had received no MMR vaccine doses or had an unknown vaccination status.
Twenty-six women (23%) were hospitalized for reasons unrelated to childbirth, while 11 (10%) developed pneumonia.
“Even though measles is an old disease, measles in pregnancy is an emerging area that we need to learn about,” said Michelle Barton, a professor at the Schulich School of Medicine & Dentistry at Western University.
Read More: Congenital Measles Reported In Pennsylvania For First Time In Decades: What Parents Should Know
The report recorded 21 pregnancy outcomes within 14 days of maternal rash onset: 19 live births and two pregnancy losses, including one miscarriage and one stillbirth.
Eight babies were born prematurely, and eight required admission to a neonatal intensive care unit (NICU).
The report noted that 13 babies had congenital measles and tested positive for the virus. Of these, six developed symptoms, including one with signs compatible with meningoencephalitis, a potentially life-threatening inflammation of the brain and surrounding membranes.
The authors said the outbreaks highlighted measles' risks to maternal and newborn health.
Many doctors and nurses treating these patients have never encountered measles, relying largely on medical training and professional guidelines to manage the infections.
The CDC recommends intravenous immunoglobulin as post-exposure prophylaxis for pregnant women without documented MMR vaccination or other evidence of immunity who are exposed to measles.
Newborns exposed to measles in the womb should also receive immunoglobulin at birth. Congenital measles can cause severe neurological complications, including subacute sclerosing panencephalitis (SSPE), a rare, progressive brain disorder.
The US is experiencing its highest measles burden in more than three decades. Since 2025, approximately 7,700 people have been infected and 13 have died, according to the figures cited in the report.
As of November 12, the CDC had confirmed 5,412 cases and six deaths in 2026. States had reported 10 deaths.
The rise in infections has coincided with declining vaccination rates and growing vaccine hesitancy. US Health Secretary Robert F. Kennedy Jr. has repeatedly questioned measles vaccine safety without scientific evidence supporting those claims.
The CDC said it would work to stop outbreaks and regain elimination status by supporting states and providing sustained national leadership.
"The measles elimination designation is not what protects Americans; vaccination does," CDC Director Erica Schwartz said.
Credit: AI Image
A new trial by Novo Nordisk found that Wegovy (semaglutide) reduced body mass index (BMI) by at least 10% in nearly 80% of children with obesity aged 6 to under 12 years.
The phase 3 STEP Young trial found that 78.7% of children receiving semaglutide achieved this reduction after 68 weeks, compared with none in the placebo group.
However, the findings raise questions about the safety of GLP-1 medications in younger children. The World Health Organization (WHO) does not recommend weight-loss medicines for treating obesity in children under 10, citing limited evidence on their long-term safety and effectiveness.
Also read: Wegovy & Zepbound Are Not Approved By US FDA For Children Under 12: So Why Are Prescriptions Rising?
The phase 3 trial evaluated once-weekly semaglutide injections in children aged 6 to under 12 with obesity. Participants also followed a reduced-calorie diet and increased their physical activity.
The findings were presented at ObesityWeek 2026 and published in The New England Journal of Medicine.
After 68 weeks:
Childhood obesity increases the risk of type 2 diabetes, high blood pressure, abnormal cholesterol levels and obstructive sleep apnea. Severe obesity can also affect a child's physical health, emotional well-being and daily life, with complications that may persist into adulthood.
The trial also found improvements in multiple cardiometabolic measures among children receiving semaglutide.
"Encouragingly, treating obesity with semaglutide was accompanied by improvements in multiple cardiometabolic measures, suggesting that effective treatments for severe childhood obesity may shift a child's trajectory back towards one of improving weight-related health," said Ania M. Jastreboff, Professor of Medicine and Pediatrics at Yale School of Medicine and Director of the Yale Obesity Research Center.
What Are The Side Effects?
Read More: Are GLP-1 Drugs Safe for Children? Study Finds Nutritional Deficiency in Nearly 17% Within a Year
Adverse events were reported in 96% of children receiving semaglutide and 93% receiving placebo. Gastrointestinal problems were the most common and occurred more frequently among children taking the drug.
Common gastrointestinal side effects associated with semaglutide include nausea, vomiting, diarrhoea, constipation and abdominal pain.
Other potential risks associated with GLP-1 treatment include gallbladder problems, pancreatitis and dehydration.
The WHO does not recommend weight-loss medicines, bariatric surgery or weight-management devices for children aged 0 to 9, as there is insufficient evidence on GLP-1 drugs in younger populations.
Instead, it recommends healthy eating, physical activity and behavioural support for children and their caregivers.
For adolescents aged 10 to 19, approved obesity medicines may be considered alongside structured lifestyle interventions.
Read More: Childhood Obesity In India To Surge To 56 Million By 2040, Says Global Report
Despite these recommendations, GLP-1 prescriptions among younger children in the US are rising.
A NYU Langone Health study analysing health records of more than 3.5 million children found that prescriptions among those aged 8 to 11 with obesity increased more than 300-fold between 2019 and June 2026.
The GLP-1 medications approved for adolescents by the US FDA are not necessarily approved for children under 12.
However, a study from Northwestern University and Ann & Robert H. Lurie Children's Hospital of Chicago flagged nutritional deficiencies among young children taking GLP-drugs.
It showed that 16.8% of children aged 10 to 17 receiving GLP-1 medications developed a nutritional deficiency within a year. Vitamin D deficiency was the most common, affecting 12.4% of patients.
Amid limited long-term safety data, experts are concerned about prescribing appetite-suppressing drugs to children who are still growing, particularly because reduced appetite could lead to inadequate calorie and nutrient intake.
© $2026 Times Horizon Private Limited